Scholars Journal of Medical Case Reports
Abbreviated Key Title: Sch J Med Case Rep
ISSN 2347-9507 (Print) | ISSN 2347-6559 (Online)
Journal homepage: https://saspublishers.com

OPEN ACCESS

Radiology

The Diagnostic Value of Gadolinium Enhancement in Brain Magnetic Resonance Imaging

Redouane Roukhsi[1*], Ben Elhend Salah[1], Hassan Doulhousne[1], Badr Slioui[1], Salah Belasri[1], Nabil Hammoune[1], Abdelilah Mouhsine[1], El Mehdi Atmane[1], El Fikri Abdelghani[1]

[1]Radiology Department, Military Hospital Avicenne, Marrakech, Marocco

DOI: https://doi.org/10.36347/sjmcr.2026.v14i04.023 | **Received:** 20.02.2026 | **Accepted:** 05.04.2026 | **Published:** 11.04.2026

***Corresponding author:** Redouane Roukhsi
Radiology Department, Military Hospital Avicenne, Marrakech, Marocco

Abstract **Review Article**

Enhancement observed after the injection of gadolinium chelates in brain magnetic resonance imaging (MRI) constitutes a fundamental pillar of neuroradiological diagnosis [1, 2]. This phenomenon, a consequence of a breach in the blood-brain barrier (BBB) or pathological angiogenesis, enables the detection, precise delineation, and phenotypic characterization of a wide spectrum of intracranial pathologies (tumors, abscesses, inflammatory processes, vascular lesions) [3]. The systematic analysis of the morphology (ring-like, nodular, homogeneous, gyriform), intensity, kinetics, and topography of the enhancement, performed at an optimal post-injection delay, is essential for guiding differential diagnosis. It is imperative to recall that a lesion that does not exhibit contrast enhancement can nevertheless be pathological, as is the case for certain low-grade gliomas or very early ischemic lesions [4]. This review aims to detail the various semiological aspects of enhancement and their pathophysiological correlates, in order to provide young radiologists with a reasoned framework for image interpretation in clinical practice.

Keywords: Brain MRI – Gadolinium – Contrast agent – Enhancement – Blood-brain barrier – Differential diagnosis.

INTRODUCTION

post-gadolinium enhancement in brain MRI represents an essential step in neuroradiological investigation [1, 5]. It results from the extravasation of the gadolinium chelate from the vascular compartment, following an alteration in the integrity of the blood-brain barrier (BBB) or in the presence of permeable neovascularization, characteristic of many pathological processes. The presence, pattern, intensity, and temporal dynamics of this enhancement provide crucial information about the histological nature, biological activity, and anatomical extent of lesions. This tool proves indispensable for highlighting subtle, sub-centimeter abnormalities invisible on native sequences and for defining the precise limits of a lesion, particularly for pre-therapeutic purposes. Its major applications include the characterization of glial and non-glial tumors, the diagnosis of infections and abscesses, the evaluation of inflammatory activity in demyelinating diseases such as multiple sclerosis, and the assessment of strokes in the subacute stage. The specific morphology of the enhancement (for example, a thin, regular ring versus a thick, nodular ring) offers primary diagnostic clues. The acquisition delay after injection is a critical technical parameter, as the characteristics of the enhancement (notably its kinetics) vary during the first minutes, providing information on vascular permeability and interstitial volume. The integrated analysis of these parameters directly guides diagnostic strategy, therapeutic planning, and the targeting of stereotactic biopsies. Although indicative of pathological activity, the absence of enhancement does not formally rule out disease, underscoring the necessity for an interpretation correlated with the entire MRI protocol. A deep understanding of the principles and mastery of the semiological interpretation of enhancement are therefore fundamental for the accurate assessment of brain lesions and optimal patient management.

PHYSICAL AND PATHOPHYSIOLOGICAL BASIS OF ENHANCEMENT

Gadolinium is a paramagnetic element from the lanthanide family. In its chelated form, used clinically for its tolerability, it has seven unpaired electrons in its 4f orbital. This configuration gives it a significant magnetic moment, enabling it to generate a powerful local magnetic field when placed in the main magnetic field of the MRI scanner [6]. In the immediate vicinity of water molecule protons (primarily in plasma and interstitial

fluid), this local magnetic field interacts with nuclear spins, considerably accelerating their return to equilibrium and predominantly shortening the longitudinal T1 relaxation time of the surrounding tissues [7].

After intravenous injection, the distribution of the gadolinium chelate is initially limited to the intravascular compartment in the absence of BBB alteration. This physiological barrier, formed by capillary endothelial cells with tight junctions, pericytes, and astrocytic end-feet, is normally impermeable to molecules of this size and hydrophilicity. However, in many pathologies (tumors, inflammation, infections, ischemia), the integrity of the BBB is compromised, either by a disruption of tight junctions or by the presence of immature and fenestrated neovascularization [8]. This results in passive extravasation (by diffusion) of the contrast agent and its accumulation in the interstitial space of the affected cerebral parenchyma. In these pathological zones, the localized shortening of T1 induced by the gadolinium concentration translates into a marked hyperintensity (bright white) on T1-weighted sequences, thus revealing in a sensitive and specific manner the presence, extent, and intensity of tissue involvement.

DIAGNOSTIC VALUE AND INTERPRETATIVE APPROACH

Contrast enhancement is a decisive element in diagnostic reasoning. Its interpretation must be systematic and multi-axial [2, 9]. The first step is to analyze the morphology of the enhancement: ring-like (annular), nodular, homogeneous, heterogeneous, gyriform (following the cortex), or leptomeningeal (involving the subarachnoid spaces). The topography of the enhanced lesion is equally crucial: intra-axial lesion (glial tumor, metastasis) versus extra-axial (meningioma, schwannoma). Correlation with complementary sequences is then imperative to refine the diagnosis:

- **Diffusion (DWI/ADC):** Allows distinction between a bacterial brain abscess (DWI hyperintensity with low ADC due to high viscosity and T2 shine-through effect) and central tumor necrosis in a glioblastoma (generally T2 hyperintensity with high ADC) [10].
- ****Magnetic susceptibility sequences (SWI/T2* GRE) ****:** Detect bleeding, calcifications, or blood breakdown products. They point, for example, towards hemorrhagic melanoma metastases, cerebral amyloid angiopathy, or a cavernoma.
- **Magnetic resonance spectroscopy (MRS)**: Reveals characteristic metabolic profiles (lactate and amino acid peaks in pyogenic abscess, marked elevation of choline in malignant tumors, lipid peak in necrosis) [12].

SEMIOLOGICAL CHARACTERISTICS OF THE MAIN ENHANCEMENT PATTERNS

1. **Ring Enhancement (Annular)**
   - **Glioblastoma (WHO Grade IV)**: Thick, irregular ring, often with a nodular and heterogeneous inner wall. It typically surrounds a central non-enhancing zone of necrosis/cavitation. Perilesional vasogenic edema is usually significant and infiltrative on FLAIR/T2 [11].
   - **Brain Metastases**: Ring is generally thin and regular, but can be thicker. Vasogenic edema is often very marked, in "fingers" pattern, and can be disproportionate to the size of the tumor nodule. Frequent cortico-subcortical topography at the gray/white matter junction.
   - **Pyogenic Brain Abscess**: Thin, regular ring, with smooth walls and sharp contours. It shows frank hyperintensity on diffusion (DWI) with a very low apparent diffusion coefficient (ADC), which is a major discriminating element compared to tumor necrosis [10]. The wall is typically T2 hypointense.
   - **Cerebral Lymphoma in the Immunocompromised Patient**: May present an irregular ring appearance, described as "eggshell" or "soap bubble," and is often multifocal.

2. **Intense and Homogeneous Enhancement**
   - **Meningioma**: Intense, uniform, and early enhancement. The presence of a "dural tail" sign – linear enhancement of the adjacent dura mater – is highly suggestive, although not pathognomonic. The lesion is extra-axial, well-defined, with a mass effect on adjacent parenchyma.
   - **Primary CNS Lymphoma in the Immunocompetent Patient**: Single or multiple masses, located periventricularly, in contact with the deep gray nuclei or the falx cerebri. Enhancement is homogeneous and intense. It typically shows diffusion hyperintensity (due to high cellularity) and marked T2 hypointensity.
   - **Vestibular Schwannoma (Acoustic Neuroma)**: Extra-axial lesion centered on the internal auditory canal (characteristic widening), often presenting a mixed cystic and solid appearance ("chocolate chip ice cream"). Enhancement of the solid portion is intense and homogeneous.

3. **Gyriform or Leptomeningeal Enhancement**
   - **Subacute Cerebral Infarct (2 to 4 weeks)**: Cortical enhancement precisely following the gyrus pattern ("gyriform" or "cortical ribbon"), within a defined arterial territory. This transient enhancement is related to neovascularization and the restoration of capillary permeability.
   - **Encephalitis**: In herpes simplex encephalitis (HSV-1), gyriform or linear cortical enhancement is frequent in the medial temporal lobes, insula, and orbitofrontal cortex. In autoimmune encephalitis (e.g., anti-NMDA-R), it may be more diffuse or multifocal.

- **Carcinomatous or Infectious Meningitis**: Thin, intense linear enhancement of the leptomeninges (arachnoid and pia mater), which can be diffuse or focal, involving the sulci, skull base, or cisterns. Consider depending on the context: tuberculosis, meningeal metastasis from an adenocarcinoma (breast, lung), or lymphomatous meningitis.

4. Nodular Enhancement (Single or Multiple)

- **Brain Metastases**: Multiple, small-sized nodules, homogeneously enhanced. SWI sequences may reveal associated microhemorrhages (melanoma, choriocarcinoma, renal cell carcinoma).
- **Active Multiple Sclerosis (MS) Plaques**: Nodules or incomplete "crescents" of enhancement (open-ring), located at the periphery of demyelinating plaques on FLAIR, corresponding to the active inflammatory front of the lesion. Involvement is typically perivenular ("central vein" sign on high-resolution sequences).
- **Granulomas (Sarcoidosis, Tuberculoma)**: Well-defined nodules, sometimes multiple, with moderate edema. Peribasilar, hypothalamic, and leptomeningeal location is frequent in neurosarcoidosis.

Absence of Enhancement (Non-enhancing Lesion)

- **Acute Ischemic Stroke (< 48h)**: The BBB is initially intact; enhancement (if it occurs) is a later phenomenon, maximal around the 2nd-3rd week.
- **Diffuse Low-Grade Gliomas (WHO Grade II)**: By definition, they do not show significant enhancement, as the BBB remains largely intact. The appearance of focal enhancement is a warning sign suggesting anaplastic transformation to a higher grade (Grade III or IV) [4].
- **Inactive (Chronic) MS Plaques**: The acute inflammatory phase responsible for enhancement has passed. The plaque appears as a non-enhancing lesion with FLAIR/T2 hyperintensity.

5. Perivascular or Linear Enhancement

- **Primary or Secondary Cerebral Vasculitis**: Segmental and linear enhancement of arterial walls (arteritis), better seen on high-resolution 3D T1 gadolinium sequences with fat suppression ("black blood" sequence).
- **Venous Angioma (Developmental Venous Anomaly)**: Typical enhancement in a "medusa head" pattern, corresponding to multiple radial venules converging towards a central dilated collecting vein, the latter being well seen on T2 hyperintensity.

MAIN PITFALLS AND STRATEGIES TO RESOLVE THEM

- **Necrotic Glioblastoma versus Pyogenic Abscess**: The distinction is a classic challenge. Diffusion MRI (DWI hyperintensity with low ADC) and spectroscopy (presence of a lactate peak and especially amino acids such as succinate, acetate, alanine in bacterial abscess) are the key sequences to decide in favor of an abscess [10, 12].
- **Primary Cerebral Lymphoma versus Glioblastoma**: Lymphoma typically shows low ADC (due to its high cellularity and high nuclear-to-cytoplasmic ratio) and homogeneous enhancement in immunocompetent patients. Glioblastoma often has a more heterogeneous ADC (mixed due to necrosis, cellularity, and edema) and more frank central necrosis.
- **Solitary Brain Metastasis versus Glioblastoma (Primitive-appearing Lesion)**: The search for a known primary, the often more marked and disproportionate vasogenic edema for a small lesion, and a cortico-subcortical location are arguments for metastasis. Conversely, an infiltrative appearance on FLAIR/T2 extending beyond the enhancement limits, crossing the midline via the corpus callosum, and spectroscopy showing a very marked elevation of choline favor glioblastoma.

CONCLUSION

Gadolinium injection in brain MRI is a key diagnostic tool. It allows for in vivo assessment of the state of the blood-brain barrier and the characteristics of lesional vascularization, thereby significantly improving the detection, anatomical delineation, and phenotypic characterization of lesions (tumoral, inflammatory, infectious, vascular). Enhancement helps distinguish active or aggressive processes from scar sequelae, guides biopsies towards the most active zones, and contributes to therapeutic follow-up by objectively evaluating response. It is therefore an essential and synergistic complement to native sequences, enabling an integrated morpho-functional analysis that is decisive for establishing an accurate diagnosis and guiding appropriate therapeutic management.

Conflict of Interest: The authors declare that they have no conflict of interest.

REFERENCES

1. Runge, V. M., & Heverhagen, J. T. (2022). The clinical utility of gadolinium-based contrast agents for magnetic resonance imaging of the central nervous system. Investigative Radiology, 57(1), 1-12.
2. Essig, M., Anzalone, N., Combs, S. E., *et al.,* (2013). MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. American Journal of Neuroradiology, 34(4), 803-817.
3. Healy, M. E., Hesselink, J. R., Press, G. A., & Middleton, M. S. (2021). Fundamentals of contrast-enhanced MRI: applications in the brain. Radiographics, 41(2), E1-E18.

4. Smits, M. (2017). Imaging of oligodendroglioma. The British Journal of Radiology, 90(1070), 20160600.
5. Kanal, E., Barkovich, A. J., Bell, C., *et al.,* (2013). ACR guidance document on MR safe practices: 2013. Journal of Magnetic Resonance Imaging, 37(3), 501-530.
6. Caravan, P., Ellison, J. J., McMurry, T. J., & Lauffer, R. B. (1999). Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chemical Reviews, 99(9), 2293-2352.
7. Rohrer, M., Bauer, H., Mintorovitch, J., Requardt, M., & Weinmann, H. J. (2005). Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Investigative Radiology, 40(11), 715-724.
8. Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013). Development, maintenance and disruption of the blood-brain barrier. Nature Medicine, 19(12), 1584-1596.
9. Wattjes, M. P., & Barkhof, F. (2014). High field MRI in the diagnosis of multiple sclerosis: high yield-high demand? Journal of Neuroradiology, 41(5), 294-304.
10. Haimes, A. B., Zimmerman, R. D., Morgello, S., *et al.,*(1989). MR imaging of brain abscesses. American Journal of Roentgenology.